Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 11/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.34 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3542968 | 0.87 | KCNH2 (0.62) | KCNH2SLC2A1SIGMAR1CXCR4 | |
| SCHEMBL3145888 | 0.86 | SLC2A1 (0.42) | KCNH2SLC2A1SIGMAR1PRKAA2 | |
| SCHEMBL2821795 | 0.84 | KCNH2 (0.46) | KCNH2 | |
| SCHEMBL2936905 | 0.83 | KCNH2 (0.59) | KCNH2SLC2A1SIGMAR1CXCR4 | |
| SCHEMBL3557358 | 0.80 | KCNH2 (0.44) | KCNH2SLC2A1SIGMAR1PRKAA2CXCR4 | |
| SCHEMBL3615723 | 0.76 | KCNH2 (0.40) | KCNH2SLC2A1KCNJ1PRKAA2 | |
| SCHEMBL3543125 | 0.75 | KCNH2 (0.53) | KCNH2SLC2A1 | |
| SCHEMBL3543122 | 0.75 | KCNH2 (0.53) | KCNH2SLC2A1 | |
| SCHEMBL3155543 | 0.75 | SLC2A1 (0.54) | KCNH2SLC2A1SIGMAR1 | |
| SCHEMBL3148857 | 0.75 | SLC2A1 (0.43) | KCNH2SLC2A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041145-B1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | GLAXO GROUP LTD (GB) | 2010-10-27 | — | — | EP | disclosed |
| US-20100004230-A1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004230-A1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | AADAC, AZI2, NNMT | KCNH2 2592/4885SLC2A1 4507/4885SIGMAR1 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.